Posted on 10 February 2013.
Lilly stops development of rheumatoid arthritis drug
(Reuters) – Eli Lilly and Co said it would stop developing its experimental rheumatoid arthritis drug tabalumab, nearly two months after data from a late-stage trial showed the drug was unlikely to prove effective. The trial, one of the three late …
Full News here – Read more on Reuters